Pediatric ENT Complaints: An Update

Melanie A. Weller, MD; Joel M. Clingenpeel, MD, MPH, MS.MEdL

This review highlights the diagnosis and management of the three most common causes of pediatric otolaryngologic complaints seen in the ED.

Among all of the causes of ear, nose, and throat (ENT) complaints, acute otitis media (AOM), bacterial sinusitis, and streptococcal pharyngitis (SP) are the most common infections prompting pediatric presentation to the ED. Through a series of case scenarios, along with key questions to help guide the clinician’s work-up, this review covers the proper evaluation and management of pediatric ENT complaints.

Case Scenario 1
A 13-month-old girl presented to the ED with a 1-day history of fever and runny nose. According to her parents, the child had been continually pulling on her ears in apparent discomfort. During history-taking, the parents further informed the emergency physician (EP) that the patient started daycare 4 months earlier and had two elementary school-aged siblings. The patient’s medical history was significant for otitis media, but the parents stated she had not been on antibiotics for over 4 months.

On physical examination, the patient’s vital signs were: blood pressure (BP), 75/50 mm Hg; temperature (T), 101.3°F; slight tachycardia; and normal age-adjusted respiratory rate (RR). Oxygen saturation was 100% on room air. The lungs were clear to auscultation and heart sounds were normal and without murmur. The otolaryngologic examination revealed copious yellow discharge from both nostrils, non-erythematous posterior oropharynx, and erythema to the right tympanic membrane (TM).

Questions to Guide the Work-Up: (1) What physical examination findings should be present for accurate diagnosis of otitis media? (2) Will this patient require antibiotics immediately, or is a “wait-and-see” approach indicated? (3) If treatment with antibiotic therapy is warranted, what are the appropriate therapeutic regimen and duration of therapy?

Otitis Media
Acute otitis media is one of the most common presentations in young children. Defined as the rapid onset of signs and
symptoms of middle ear inflammation, in conjunction with middle ear effusion (MEE), AOM can develop secondary to a viral or bacterial infection. It is estimated that more than 80% of the pediatric population will experience at least one episode of AOM by age 3 years.1-3

Risk factors for AOM include upper respiratory infection (URI), daycare attendance, siblings, parental smoking, and formula-feeding versus breastfeeding. The patient’s history may include rapid-onset otalgia, fever, irritability, anorexia, and concurrent URI symptoms, as well as other nonspecific symptoms (eg, ear rubbing and/or pulling, crying, changes in behavior and sleep patterns).2-4 In general, otalgia and ear-rubbing in the nonverbal patient seem to have the best predictive value for AOM.3

Signs and Symptoms
A normal TM should be translucent and pearly gray, with visible landmarks of the manubrium of malleus and pars flaccida. A TM that is bulging, cloudy, and immobile is the most consistent finding in AOM, with bulging having a specificity of 97%. Redness of the tympanic membrane is not a useful predictor of AOM as this finding is noted in upward of 30% of pediatric patients on general examination but in <1% of AOM diagnoses in the absence of a bulging TM.2-5

Diagnosis
Pneumatic otoscopy is the gold standard for diagnosing for MEE; however, this examination can be difficult in younger, often uncooperative, patients. A TM that does not perceptibly move with either positive or negative insufflation pressure greatly enhances the diagnostic accuracy for MEE over the use of visible eardrum characteristics alone.2-5

Acute otitis media is a clinical diagnosis and does not require imaging studies or laboratory evaluation unless more serious processes, such as skull fracture, mastoiditis, or intracranial abscess, are being considered.2-3

Treatment and Management

Analgesia. The first step in managing patients with AOM is to provide analgesia. In most cases, acetaminophen in patients over 2 months of age, or ibuprofen in patients over 6 months of age, are adequate choices for managing pain. When either of these analgesics is administered in the clinic/ED setting, patients should be monitored to assure adequate pain relief prior to discharge.

While topical agents such as combination antipyrine-benzocaine suspensions were commonly given in the past to alleviate the pain associated with AOM, there are limited data to support their effectiveness. As such, in July 2015, the US Food and Drug Administration ordered manufacturers to halt production on these unapproved prescription products.3,4,6 There are also no randomized controlled trials (RCTs) to support the use of decongestants or antihistamines for resolution of AOM or otalgia.3,7

Antibiotic Therapy. The most common bacteria associated with AOM are Streptococcus pneumoniae, nontypeable Hemophilus influenzae, and Moraxella catarrhalis. In 30% of patients, the causative etiology is viral. When the decision is made to treat AOM, high-dose amoxicillin is still considered the first-line treatment, despite ever evolving susceptibilities of bacteria. Alternate therapies include amoxicillin-clavulanate, azithromycin, cefdinir, ceftriaxone, and sulfamethoxazole-trimethoprim; however, treatment with azithromycin or sulfamethoxazole-trimethoprim should be reserved for patients who have a history of anaphylactic reaction to penicillin (Table 1).

When a child is noted to have been treated with amoxicillin within a 30-day period or who has concurrent conjunctivitis, amoxicillin-clavulanate is considered the first-line treatment.2-4,7,8 The current American Academy of Pediatrics (AAP) guidelines recommend 10 days of antibiotic therapy for children younger than age 2 years, and 5 to 7 days for children older
than age 2 years who have uncomplicated AOM. Intramuscular (IM) ceftriaxone is an acceptable first-line agent in a child who is unable to tolerate oral medications or who is suffering persistent emesis. Intramuscular ceftriaxone can be given as a single dose of 50 mg/kg, though the patient should be followed closely as studies show that a second dose may be necessary 5 to 7 days later to prevent infection recurrence. The IM dose of ceftriaxone 50 mg/kg can also be given if treatment with other antibiotics fails to resolve the AOM (failure is defined as no improvement in the patient’s condition 48 to 72 hours from treatment). In such cases, ceftriaxone is given in three consecutive doses.3,4,7

**Wait-and-See Approach.** Studies of patients whose AOM was confirmed via culture (19% were positive for *S pneumoniae*, 48% for *H influenza*, and 78% for *M catarrhalis*) showed bacterial clearance without antibiotic intervention.4 Based on these findings, the 2013 revised AAP evidence-based clinical practice guidelines indicate an initial watching-and-waiting period combined with pain management for patients older than 6 months of age who are diagnosed with unilateral AOM in the absence of severe symptoms (ie, fever is lower than 102.2°F or patient has severe otalgia).4 A period of observation prior to treatment is also endorsed for children older than age 2 years who exhibit nonsevere symptoms—even if they have bilateral disease.4

Conversely, all patients younger than age 6 months and all children with severe symptoms should be treated with antibiotics at diagnosis.3,4 The wait-and-see approach, recommends an observation period of 24 to 48 hours for children in the lower risk group prior to antibiotic administration. Delayed antibiotic administration can be performed by a physician

---

**Table 1. Recommended Antibiotic Therapy for Acute Otitis Media and Acute Bacterial Sinusitis**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Maximum Dosage</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amoxicillin</td>
<td>80-90 mg/kg/d, divided twice a day</td>
<td>2,000 mg per dose</td>
<td></td>
</tr>
<tr>
<td>Amoxicillin-</td>
<td>80-90 mg/kg/d</td>
<td>2,000 mg per dose</td>
<td>Use 14:1 amoxicillin:clavulanate ratio (ES-600 suspension)</td>
</tr>
<tr>
<td>clavulanate</td>
<td>(amoxicillin component divided twice a day)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cefdinir</td>
<td>14 mg/kg/d daily or divided twice a day</td>
<td>600 mg/d</td>
<td>May cause dark red stool (resembling melena), particularly in infants on iron-fortified formulas</td>
</tr>
<tr>
<td>Azithromycin</td>
<td>10 mg/kg/d, day 1</td>
<td>500 mg, day 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5 mg/kg/d, days 2-5</td>
<td>250 mg, days 2-5</td>
<td></td>
</tr>
<tr>
<td>Sulfamethoxazole-</td>
<td>8-12 mg/kg/d, trimethoprim component</td>
<td>160 mg per dose</td>
<td></td>
</tr>
<tr>
<td>trimethoprim</td>
<td>divided twice a day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>50 mg/kg intramuscularly for 1 day, with maximum of 1,000 mg per dose*</td>
<td>1,000 mg</td>
<td>Acute otitis media indications: *If child is unable to tolerate oral route *For cases of oral treatment failure</td>
</tr>
<tr>
<td></td>
<td>50 mg/kg intramuscularly for 3 consecutive days, with a maximum of 1,000 mg per dose*</td>
<td>1,000 mg</td>
<td></td>
</tr>
</tbody>
</table>
in an office/ED follow-up or as a safety-net antibiotic prescription (SNAP) sent home with the family on the initial ED encounter.2-4,8,9

**Case 1 Resolution**

Given this patient’s unilateral and non-severe symptoms (minor otalgia, fever <102.2°F, age older than 6 months, and no recent antibiotic use), she was treated with oral ibuprofen. At discharge, the parents were given a 10-day SNAP prescription of high-dose amoxicillin (90 mg/kg/d, divided into two daily doses) and instructed to fill the prescription only if the patient’s otalgia did not improve in 1 or 2 days.

**Case Scenario 2**

A 5-year-old boy was presented for evaluation by his parents, who stated that their son had been sick since he had started kindergarten in the fall. The patient had a 10-day history of cough, thick runny nose, and facial pain, and a 1-day history of new-onset fever and headache. His parents further noted that the patient had been seen by his pediatrician several times over the past week. At each of these visits, the pediatrician had informed them that their son had a virus.

Vital signs on examination were: BP, 100/60 mm Hg; heart rate (HR), 112 beats/min; normal age-adjusted RR; and T, 102.6°F. Oxygen saturation was 100% on room air. The patient did not appear toxic, his lungs were clear on auscultation, and there were no other clinical signs suggestive of meningitis. The otolaryngologic examination revealed bilateral thick mucoid drainage and visible edema and erythema of the nasal turbinates. The patient was noted to have some facial pain in the maxillary area bilaterally.

**Questions to Guide the Work-Up:**

1. Does the patient have a prolonged URI or pediatric sinusitis, and what differentiates the two conditions?
2. What sinusites are present in a 5-year-old patient?
3. What treatment modalities are available for sinusitis?
4. Is imaging of the sinuses helpful in confirming the diagnosis?

**Acute Bacterial Sinusitis**

Rhinosinusitis is an inflammation of the mucosal lining of the nasal passages and paranasal sinuses. Most cases occur secondary to a viral URI and resolve spontaneously in 99% of the pediatric population.10,11

Acute bacterial sinusitis (ABS) is an inflammation of the same mucosal lining of the nasal passages secondary to bacterial overgrowth that lasts more than 10 days, with complete resolution by 30 days.12,13 When evaluating a pediatric patient for ABS, it is important to consider the sinus growth and development: If the sinus is not yet formed, it therefore cannot be the location of an ABS.13 The ethmoid and maxillary sinuses are present at birth, aerated within 4 months of life, and are fully developed by age 12 years. The sphenoid sinuses begin development around age 3 years, are aerated by age 7 or 8 years, and are fully developed by age 18 to 20 years. The frontal sinuses begin development around age 8 years and are aerated and fully developed by age 12 to 15 years.10,13,14 While most guidelines focus on children older than age 1 year (due to very small infantile sinuses), ABS does occur in children younger than age 1 year.12,14

**Signs and Symptoms**

Differentiation between a viral URI/rhinosinusitis and ABS is a challenge and can be based upon severity of symptoms as well as length of illness. Symptoms of ABS are typically present and persistent for more than 10 days, without improvement. Continuing illness and worsening of symptoms are identifying features of ABS given most viral URIs gradually resolve within a 10-day timeframe. Other common symptoms include milky/thick nasal discharge, fever, predominantly nocturnal cough, and headache. Other less common symptoms include facial pain, toothache, malodorous breath, and periorbital edema. On physical examination, erythema and edema of the turbinates, as well as reproducible pain over aerated sinuses, are suggestive of ABS.10-14
Diagnosis
In the acute care setting, diagnosis of ABS should be clinical in nature. Neither imaging nor laboratory work-up is generally required secondary to their poor diagnostic specificity for ABS. The bacteria involved in ABS are similar to those associated with AOM, with *S pneumonia*, nontypeable *H influenza*, and *M catarrhalis* being the predominant organisms.10-15

Treatment and Management
Treatment of ABS is generally recommended once the diagnosis is made, though this is based largely on expert opinion as there are limited RCTs available.13 However, available studies do show a more rapid improvement in children on antibiotic therapy than those on placebo.15,16

**Antibiotic Therapy.** Amoxicillin remains the antimicrobial agent of choice for first-line treatment of uncomplicated ABS for situations in which antimicrobial resistance is not suspected. In communities with a high prevalence of nonsusceptible *S pneumoniae* (>10%, including intermediate- and high-level resistance), treatment may be initiated at 80 to 90 mg/kg/d in two divided doses, with a maximum of 2 g per dose.

Patients presenting with moderate to severe illness, as well as those who are younger than 2 years, attend childcare, or have recently been treated with an antimicrobial, may receive high-dose amoxicillin-clavulanate as initial therapy given the elevated beta-lactamase production of the common bacteria that cause ABS.

Second-line alternatives include azithromycin, cefdinir, and sulfamethoxazole-trimethoprim (Table 1). There are data to suggest higher rates of decreased susceptibility of *S pneumonia* and *H influenza* to third-generation cephalosporins, and the addition of clindamycin may be warranted when utilizing those medications. Treatment is recommended for 10 to 14 days, though improvement should be noted within 1 to 3 days.10-12,14-17

**Adjuvant Therapy.** Additional therapies include nasal irrigation, decongestants, antihistamines, and intranasal steroids; however, there are only anecdotal reports of their efficacy in providing symptom relief. Therefore, there are insufficient evidence-based data to support or refute the role of these adjuvant therapies in treating pediatric patients with ABS.9,13
Case 2 Resolution
The prolonged duration and severity of symptoms (high fever and headache) and the gradual worsening of the clinical course (ie, late-onset fever) in this patient all suggest ABS rather than a simple prolonged URI. The physical examination findings of inflamed turbinates and facial pain further increase the specificity for ABS. The patient was started on oral amoxicillin-clavulanate with planned treatment for 14 days. At discharge, his parents were instructed to follow-up with the patient’s pediatrician in 3 days to ensure a degree of clinical resolution.

Case Scenario 3
A 4-year-old boy was presented by his parents for evaluation of a 2-day history of a persistent and unimproved sore throat. The patient’s mother indicated that the child’s oral T upon returning home earlier from preschool was 101.2°F. She further noted that her 17-month-old daughter and 8-year-old son also experienced similar symptoms which had self-resolved. Triage vital signs were: T, 100.8°F, orally; BP, HR, and RR were all within normal limits. Oxygen saturation was 100% on room air.

On physical examination, the child was noted to have anterior cervical lymph nodes bilaterally and an erythematous oropharynx with exudate noted on both tonsils. There were no cutaneous abnormalities, nasal edema, erythema, or drainage. Based on the clinical examination, the EP was suspicious for SP.

Questions to Guide the Work-Up:
1. Is SP diagnosed based on clinical findings alone in this patient’s age group? (2) At what age in the pediatric population is it appropriate to perform a rapid streptococcal antigen test? (3) Are there medications other than antibiotics that are beneficial in treating symptomatic SP?
Streptococcal Pharyngitis

Streptococcal pharyngitis is a clinical condition caused by group A beta-hemolytic *S pyogenes*. This bacterium is responsible for multiple conditions, including pharyngitis, skin infections, poststreptococcal glomerulonephritis, and rheumatic fever, as well as invasive syndromes. (This case focuses solely on SP).

Pharyngitis can occur secondary to a viral or bacterial infection, and SP is the most common cause of pediatric bacterial pharyngitis. It is estimated that children aged 5 to 15 years are more commonly diagnosed with SP, although approximately 24% of children younger than age 5 years with pharyngitis symptoms will be ultimately diagnosed with SP.

Signs and Symptoms

Typical symptoms include fever, pharyngitis, generalized abdominal pain, nausea, vomiting, headache, and absence of viral URI symptoms (eg, cough, nasal discharge). However, younger patients with SP may have clinical findings of prolonged nasal drainage and excoriated nares. Examination findings may include swollen and tender anterior cervical lymph nodes; generalized edema and erythema of the posterior pharynx; tonsillar exudates; and palatal petechiae.

Diagnosis

**Centor Criteria.** The Centor criteria were developed to assist practitioners in identifying patients with potential SP. Criteria for patients older than age 15 years include fever, absence of cough, tonsillar exudates, and tender anterior cervical lymphadenopathy. A modified Centor criteria was later established to include children older than age 5 years, with children between ages 5 and 15 years being the fifth variable in the modified score. In general, patients with a score of 4 or 5 (presence of each variable = 1 point) are most likely to test positive for SP on rapid antigen testing (RAT) or culture.18-20

**Swab, Rapid Antigen Testing, and Culture.** Swabbing the throat and RAT and/or culture should be performed in most children with suspected SP because the clinical features alone do not reliably discriminate SP from viral pharyngitis. Rapid antigen testing is only specific for group A beta-hemolytic streptococcal species, which is the only streptococcal species that is routinely treated with antibiotics in the setting of acute pharyngitis. It is unlikely for a patient with a score of 0 or 1 to have SP, and several sources suggest neither testing nor treating this cohort, but rather to consider an alternative diagnosis.18-20

Within the population of children and young adolescents, due to a RAT sensitivity of 70% to 90%, a negative result should always be backed-up by a throat culture, and treatment initiated if results of the culture are later found to be positive. As the current generation of RAT tests have a high specificity, a positive RAT does not necessitate a back-up culture, and treatment is indicated without further investigation.19,20

Routine RAT is not recommended in children younger than age 3 years as patients in this age group are at low-risk of developing rheumatic fever. One notable exception for these very young children would be if there are siblings in the home with confirmed SP, in which case, RAT should be considered in the clinical context of SP.21 Adolescents over age 15 years are another cohort with a low likelihood of developing rheumatic fever, though they can develop other poststreptococcal complications, such as glomerulonephritis.

The US Centers for Disease Control and Prevention/American Academy of Family Practitioners (AAFP) guidelines suggest that pharyngitis in older adolescents can be approached in a similar fashion to adults, with empiric therapy for a Centor score of 3 or 4, RAT (without the need for follow-up culture) for Centor score of 2, and neither testing nor treating patients with a score of 0 or 1.19
Treatment and Management

Streptococcal pharyngitis is treated mainly to prevent the poststreptococcal complications of rheumatic fever, though it will not prevent poststreptococcal glomerulonephritis. Treatment of SP also facilitates resolution of symptoms and return to baseline activities.

**Antibiotic Therapy.** Patients who have a positive RAT or a follow-up throat culture positive for group A streptococcus should be given antibiotics. The gold standard treatment is penicillin V orally for 10 days. Other medication choices include amoxicillin orally for 10 days or a single IM dose of benzathine penicillin G. For penicillin-allergic patients, alternative regimens include oral azithromycin, cephalaxin, and clindamycin (Table 2).19-22

**Corticosteroid Therapy.** The use of corticosteroids for symptom control of SP in pediatric patients is controversial. Although the Infectious Disease Society of America does not recommend corticosteroid therapy in the treatment of SP, several studies show such therapy (namely dexamethasone), improves pain in children and adolescents diagnosed with SP, but without significant change to the overall disease course.21,23-26

Case 3 Resolution

The patient had a modified Centor criteria score of 4, as well as siblings with similar symptoms. In following current guidelines, the EP performed a RAT and back-up culture. The RAT was negative in the ED, but the back-up culture was subsequently positive, and the child was started on a 10-day course of oral amoxicillin.

---

**Table 2. Recommended Antibiotic Therapy for Streptococcal Pharyngitis**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Route</th>
<th>Dose</th>
<th>Maximum Dosage</th>
<th>Length of Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penicillin V</td>
<td>Oral</td>
<td>250 mg twice a day in patients weighing &lt;27 kg; 500 mg twice a day to three times a day in patients weighing &gt;27 kg</td>
<td>1,000 mg/d</td>
<td>10 days</td>
</tr>
<tr>
<td>Amoxicillin</td>
<td>Oral</td>
<td>50 mg/kg/d once a day or divided twice a day</td>
<td>1,000 mg/d</td>
<td>10 days</td>
</tr>
<tr>
<td>Benzathine penicillin G</td>
<td>Intramuscular</td>
<td>600,000 U in patients weighing &lt;27 kg; 1,200,000 U in patients weighing &gt;27 kg</td>
<td>Once</td>
<td></td>
</tr>
<tr>
<td>Cephalexin</td>
<td>Oral</td>
<td>40 mg/kg/d divided twice a day</td>
<td>1,000 mg/d (500 mg per dose)</td>
<td>10 days</td>
</tr>
<tr>
<td>Azithromycin</td>
<td>Oral</td>
<td>12 mg/kg/d</td>
<td>500 mg/d</td>
<td>5 days (Note: Dosing strategy is different than is typical for this drug)</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>Oral</td>
<td>21 mg/kg/d divided three times a day</td>
<td>900 mg/d (300 mg per dose)</td>
<td>10 days</td>
</tr>
</tbody>
</table>
Conclusion
When evaluating pediatric patients presenting with ENT signs and symptoms such as ear pain and erythema, fever, sore throat, nasal congestion and discharge, a thorough physical examination and history-taking—including recent illness of any siblings—along with testing when indicated, is essential to guide the diagnosis and determine appropriate treatment and management. In addition to administering antibiotic therapy when such is warranted, the EP should provide appropriate analgesia to manage the patient’s pain and assure relief prior to discharge.

References